Eli Lilly and Company Stock News

Eli Lilly will offer weight-loss drug Zepbound in a new form at roughly half the list price. Eli Lilly stock fell, along with several others.

The High Quality Dividend Stock Investable Universe is a rules-based approach to finding the best dividend stocks to invest in. The universe is made up of 50 stocks with a focus on identifying companies with strong growth metrics and proven to be winners in the past. A custom valuation model is applied to the investable universe to determine buy, hold or trim ratings for each stock.

Eli Lilly & Co. LLY, -0.23% said Tuesday patients can now access 2.5 mg and 5 mg single-dose vials of its weight-loss treatment Zepbound with an on-label prescription at a discount of at least 50% over other incretin medicines for obesity. The drug company said the vials are available through its LillyDirect self-pay channel.

Eli Lilly said it has begun selling single-dose vials of its popular weight-loss drug Zepbound in the U.S., aimed at patients who cannot get the cost of the medicine reimbursed through their health insurance plans.

Pfizer Inc. on Tuesday unveiled a new online platform designed to help simplify and coordinate healthcare for consumers, adding momentum to an emerging trend in big pharma that has drawn criticism from some provider groups and policy experts.

Eli Lilly released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to increase access for patients without insurance coverage for the highly popular injection. The move also aims to expand the U.S. supply of Zepbound amid soaring demand and ensure patients are safely accessing the treatment as cheaper copycat versions of the drug gain traction.

Distributed through LillyDirect®'s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesity INDIANAPOLIS , Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, signifi...

Eli Lilly and Co. NYSE: LLY is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, known as Mounjaro for type 2 diabetes, and Zepbound for obesity. Its stock is trading back near its all-time high at $972.52.